Signet-Ring Cell/Histiocytoid Carcinoma: Report of Two Cases and Systematic Review of the Literature on the Epidemiology, Clinical Characteristics, and Pathological and Molecular Findings.
Irmina Maria MichalekFlorentino Luciano Caetano Dos SantosJakub ZwolinskiWojciech OlszewskiAdam GałazkaMonika Prochorec-SobieszekMonika DurzynskaPublished in: The American Journal of dermatopathology (2023)
Signet-ring cell/histiocytoid carcinoma (SRCHC) is a rare appendageal tumor, mainly considering eyelids, more rarely axillae. This article describes 2 novel SRCHC cases of 71- and 66-year-old men and systematically reviews the literature on SRCHC. Of all cases reported in the literature, 73 (91.2%) were men and 7 (8.8%) were women. The median age at diagnosis was 71 years. Skin changes were located in the eyelids (68%) and axillae (32%). In all tested cases, SRCHC cells expressed CK7, CKAE1/AE3, EMA, CAM5.2, and AR and PIK3CA mutations. Future research should determine whether AR/PIK3CA-targeted therapies influence patients' survival.
Keyphrases
- single cell
- systematic review
- end stage renal disease
- cell therapy
- newly diagnosed
- ejection fraction
- protein kinase
- induced apoptosis
- chronic kidney disease
- polycystic ovary syndrome
- prognostic factors
- middle aged
- risk factors
- randomized controlled trial
- mesenchymal stem cells
- current status
- cell cycle arrest
- adipose tissue
- patient reported outcomes
- cell death
- oxidative stress
- wound healing